Johnson & Johnson (JNJ), Dendreon Corporation (DNDN): A Magical Drug that Could Change Lives

Page 1 of 2

The biotech sector is perhaps the most volatile and risk-prone sector in the market, but investors still love it. Medical science is leaping forward and new drugs keep hitting the Street, but the hunt for the “safer and more effective drug” is always on. It’s for this reason that we often see contrarians being rewarded massively for their daring positions. The company in focus is Dendreon Corporation (NASDAQ:DNDN), and here are a few reasons why I think it could prove to be a great investment.

Johnson & Johnson (JNJ)

The magic drug

To begin with, Dendreon has absolutely ridiculous fundamentals. From towering debt/equity to plummeting profitability, it gets filtered out as a poor stock. But history doesn’t ascertain the future, right?

Dendreon Corporation (NASDAQ:DNDN) was able to develop an immunotherapy treatment called Provenge that attacks cancer cells by boosting a person’s immunity. This not only contributes to cancer reduction/remission, but also improves a person’s defense system against common illnesses like the flu or infections. Unlike chemotherapy and other radiation treatments, this is a more natural approach, but also has its share of side effects. Its common side effects include chills and fatigue, but it’s still way better than chemotherapy, which causes hair loss, bleeding, and body aches. Provenge competes with Xtandi, developed by Medivation Inc. (NASDAQ:MDVN), and Zytiga, developed by Johnson & Johnson (NYSE:JNJ).

Studies have shown that prostrate specific serum antigen levels shrank by up to 85% when Xtandi was used for a month. Zytiga springs into action soon after it has been prescribed, but Provenge takes at least 2-3 months to even show signs of recovery. But, the good thing is that Provenge uses immunotherapy, which is considered to have fewer side effects than its peers.

This is indeed a revolutionary breakthrough, and just like any new business model, it, too, had a painfully long fertility period. Shares of Dendreon were continuously hammered as the company reported a streak of lower-than-expected sales of its cancer treatment procedure, Provenge. This, coupled with poor margins, brought financial havoc upon the company. For the recent quarter, the company reported a net loss of $0.26 per share, compared to a profit of $0.26 per share in Q4 2011. Its quarterly revenue also plunged to $85 million, down from $202 million in Q4 2011.

But, the Street was absolutely delighted, as it was expecting a loss of $0.55 per share. Moreover, the company reported annual sales to the tune of $325.3 million, up from $213.5 million in FY11. Its streak of poor sales finally seems to be over. Its peers are also performing well. Medivation’s Xtandi was launched in Sept. 2012. Its first full quarter sales stood at a solid $57 million and the management expects its Xtandi sales to cross $100 million, and even beat the street’s estimates. Johnson & Johnson (NYSE:JNJ) also recorded impressive sales growth of 6.8% for Zytiga, but its relatively weaker FY13 guidance disappointed the street. For FY13, Johnson & Johnson is expecting to earn $5.35-$5.45 per share.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Countries with the Highest Suicide Rates

The 10 Most Technologically Advanced Countries in the World

The 10 Safest Countries in the World to Live in Peace

The 10 Top Selling Smartphones in the World 2014

The 12 Biggest Shopping Centers in the World

The 10 Friendliest Countries in the World

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!